Navinci partners with Biomol GmbH for the distribution of Naveni products in Germany
”Germany is an important market for Navinci and Biomol is a great organization for us to partner with. They are a highly skilled sales and marketing team that applies modern and forward-thinking methodologies. We look forward to working closely with Biomol to bring the NaveniTM proximity ligation assay kits to the German life science research and industry” says Robert Gunnarsson, CEO Navinci Diagnostics AB.
”With the addition of the NaveniTM product line to our broad portfolio of antibodies and research reagents, we enable our customers to specifically study the interplay of proteins in tissues and cells. Founded on the legacy as the original developer of the in situ proximity ligation assay, the Navinci team is dedicated to engaging with their customers to support and adapt to their needs, which resonates well with our way of doing business” says Wilco van Hamond, CEO Biomol GmbH.
Navinci announces collaboration with Cambridge Bioscience in the UK and Ireland
Today we are pleased to announce our collaboration with Cambridge Bioscience to distribute Naveni products in the UK and Ireland!
”We are very pleased to partner with Cambridge Bioscience and their highly skilled sales and marketing team. Their long experience of serving customers in the life science research and industry will catalyze the accessibility of the NaveniTM proximity ligation assay kits in the UK and Ireland market.”
Robert Gunnarsson, CEO Navinci Diagnostics AB
”The Naveni products will be a great complement to our broad portfolio of antibodies and other research reagents, enabling our academic and pharma customers to study the interplay of proteins in tissues and cells. Navinci’s innovative products, combined with their expertise as the original developers of the proximity ligation technology, provides a good foundation for collaboration with our expert sales and support teams. Our aim is always to provide best-in-class solutions and support to our customers.”
Mike Kerins, Managing Director Cambridge Bioscience Limited